

# Microalbuminuria in Type 2 Diabetes and Hypertension

## A marker, treatment target, or innocent bystander?

SEEMA BASI, MD, MSCI<sup>1</sup>  
PIERRE FESLER, MD<sup>2</sup>

ALBERT MIMRAN, MD<sup>2</sup>  
JULIA B. LEWIS, MD<sup>3</sup>

**A**lbuminuria is a well-known predictor of poor renal outcomes in patients with type 2 diabetes and in essential hypertension (1–4). Albuminuria has also been shown more recently to be a predictor of cardiovascular outcomes in these populations (5–8). There is emerging data that reduction of albuminuria leads to reduced risk of adverse renal and cardiovascular events (9–12). It has become increasingly clear that albuminuria should not only be measured in all patients with type 2 diabetes and hypertension, but also steps should be taken to suppress albuminuria to prevent future renal and cardiovascular adverse events. This review discusses the measurement of albuminuria and summarizes the current literature on the association between albuminuria and adverse cardiovascular and renal outcomes in type 2 diabetes and hypertension. It also summarizes the evidence that reduction of albuminuria leads to improvement in the risk profiles of these patients.

### DEFINITION AND MEASUREMENT OF ALBUMINURIA

— Microalbuminuria is defined as levels of albumin ranging from 30 to 300 mg in a 24-h urine collection (13). Overt albuminuria, macroalbuminuria, or proteinuria is defined

as a urinary albumin excretion of  $\geq 300$  mg/24 h. Urinary albuminuria comprises 20–70% or urinary total protein excretion. Measuring urinary albumin excretion by dipstick without simultaneously measuring creatinine is subject to false-negative and false-positive results due to variations in urine concentration caused by hydration level (13). Although urinary dipsticks are acceptable for quick screening, other more precise measurements should be done to quantify urinary albumin excretion rates (AERs). Albuminuria can be measured in several ways (Table 1): 1) measurement of albumin-to-creatinine ratio (ACR) in a random or first morning spot collection, 2) 24-h urine collection with measurement of creatinine to verify adequacy of the collection, and 3) timed (4-h or overnight) urine collections (13). Although the 24-h urine collection would overcome issues of diurnal variation in albumin excretion, it is subject to collection errors. The Kidney Disease Outcomes Quality Initiative guidelines state that ACR measurement in a first-morning spot urine collection is adequate and a timed urine collection is not necessary (14). However, because women excrete less creatinine than men and microalbuminuria is based on a fixed amount of urinary albumin excretion per day, the definitions of microalbuminuria

are different in men and women when using ACRs (15).

Microalbuminuria was first defined by Mogensen (1) and others as 30–300 mg urinary albumin excretion per 24 h. However, at the time, there was not widespread use of inhibitors of the renin-angiotensin system. As noted below, inhibition of the renin-angiotensin system decreases urinary albumin excretion, and drugs to inhibit the renin-angiotensin system are currently in wide use. A patient being treated with drugs that inhibit the renin-angiotensin system, with urinary albumin excretion of 30–300 mg per 24 h, would have likely had much higher levels of AER without such drugs when Mogensen first defined microalbuminuria. Hence, most patients who have urinary albumin excretion in the microalbuminuria range currently have more advanced disease than patients in the past. In addition, microalbuminuria and albuminuria or proteinuria are part of a clinical continuum of risk and prognosis.

### PREVALENCE OF MICROALBUMINURIA IN ESSENTIAL HYPERTENSION

— Reported figures concerning the prevalence of albuminuria in essential hypertension have yielded variable results due to the chosen cutoff value, patient selection, and more importantly the duration of hypertension and of prior treatment.

In a cohort of 787 patients aged 18–72 years, studied after discontinuation of antihypertensive treatment for at least 4 weeks, a prevalence of microalbuminuria (AER  $\geq 30$  mg/24 h) of 8% was observed (16). A prevalence of microalbuminuria of 6% was found in a cohort of 1,041 younger patients (aged 18–45 years) with untreated mild hypertension (140–159/90–99 mmHg) (17). Analysis of the population of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study of 8,029 subjects (aged 55–80 years) with stage II–III essential hypertension (sitting office blood pressure of 160–200/95–115 mmHg) and electrocardiographic left ventricular hypertrophy (LVH) and using a single cutoff value

From the <sup>1</sup>University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey; the <sup>2</sup>Department of Internal Medicine, Hôpital Lapeyronie, Montpellier, France; and <sup>3</sup>Vanderbilt University Medical Center, Nashville, Tennessee.

Address correspondence and reprint requests to Julia B. Lewis, MD, Vanderbilt University Medical Center, 1161 21st Ave. South and Garland, Division of Nephrology, S-3223 MCN, Nashville, TN 37232-2372. E-mail: julia.lewis@vanderbilt.edu.

J.B.L. has been a paid consultant for Astra Zeneca and Novartis.

This article is based on a presentation at the 1st World Congress of Controversies in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this article were made possible by unrestricted educational grants from MSD, Roche, sanofi-aventis, Novo Nordisk, Medtronic, LifeScan, World Wide, Eli Lilly, Keryx, Abbott, Novartis, Pfizer, Genex Biotechnology, Schering, and Johnson & Johnson.

**Abbreviations:** ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; ARB, angiotensin receptor blocker; GFR, glomerular filtration rate; IDNT, Irbesartan Diabetic Nephropathy Trial; LIFE, Losartan Intervention for Endpoint Reduction in Hypertension; LVH, left ventricular hypertrophy; PREVEND, Prevention of Renal and Vascular End-Stage Disease; RENAAL, Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; SAP, systolic arterial pressure.

DOI: 10.2337/dc08-s249

© 2008 by the American Diabetes Association.

Table 1—Measurement of albuminuria

	Normal	Microalbuminuria	Macroalbuminuria	Advantages	Disadvantages
Dipstick for Protein	—	—	+	Convenience	Dependent on level of hydration
24-h protein (mg)	<150	<500	≥500	Overcomes problem of diurnal variation in excretion	Subject to collection errors
24-hour albumin (mg)	<30	30–300	>300	Overcomes problem of diurnal variation in excretion	Subject to collection errors
Timed collection (μg/min)	<20	20–200	>200	Overcomes problem of diurnal variation in excretion	Subject to collection errors
Spot collection (μg albumin/mg creatinine)	<30	30–300	>300	Convenience Not dependent on hydration level Most reproducible	Ratios vary based on sex

for AER in men and women ( $\geq 3.5$  mg/mmol creatinine corresponding to 30 mg/24 h) revealed a prevalence of microalbuminuria of 26%. Before inclusion, treatment was discontinued for 2–4 weeks; this may have increased the prevalence of microalbuminuria (18). Of interest, it was recently shown that 70% of patients with electrocardiographic LVH included in the LIFE study have echocardiographic LVH (left ventricular mass index  $\geq 104$  in women and  $\geq 116$  g/m<sup>2</sup> in men) (19).

In a subgroup of 376 never-treated individuals aged  $\geq 40$  years from our personal cohort of essential hypertensive patients, analysis of the prevalence of target organ damage (LVH defined as left ventricular mass index  $\geq 110$  in women and  $\geq 125$  g/m<sup>2</sup> in men and microalbuminuria defined as AER  $\geq 30$  mg/24 h) showed that 27% had LVH alone and 6% had microalbuminuria alone, whereas both abnormalities were present in 10%

of patients and 57% were free of target organ damage. Overall, the presence of microalbuminuria was found in 16%, whereas LVH was found in 37% of the population. In addition, 21% of patients with LVH were classified as microalbuminuric, whereas 59% of patients with microalbuminuria had LVH, thus suggesting that microalbuminuria is a good predictor of the presence of LVH. Of interest, male patients were more frequently affected by the combination of LVH and microalbuminuria than women (15 vs. 4% in the population aged  $\geq 40$  years). The group of patients with both LVH and microalbuminuria had the highest arterial pressure level, a larger proportion of smokers, and a longer duration of hypertension than patients with only one isolated target organ damage. Importantly, urinary sodium excretion taken as an index of dietary sodium intake was markedly higher than in the other groups.

### FACTORS INFLUENCING THE RELATIONSHIP BETWEEN ARTERIAL PRESSURE AND ALBUMINURIA

— It is generally accepted that arterial pressure, mainly systolic arterial pressure (SAP) and to a lesser extent pulse pressure, is a major determinant of albuminuria. The slope of the relationship between albuminuria and SAP is steeper in men than in women. In fact, albuminuria remains almost unaltered with SAP within the normotensive range (<140 mmHg). In contrast, the response of the left ventricle to SAP is linear within the whole range of SAP (20). Some factors were shown to influence this relationship such as oral contraception in nonmenopausal women (21) and impaired glucose tolerance or diabetes. In 2002, du Cailar et al. (22) assessed the influence of sodium intake (estimated by two consecutive determinations of 24-h natriuresis) on the relationship between SAP and target organs (i.e., left ventricular mass index and AER) in a large cohort of 839 normotensive and never-treated hypertensive subjects aged 15–70 years. It was observed that increasing dietary sodium was associated with an increasingly steeper slope of the relationship of SAP versus AER or left ventricular mass index. As shown in Fig. 1, the prevalence of LVH or microalbuminuria was higher in hypertensive patients aged  $\geq 40$  years with a natriuresis above a median of 147 mmol/24 h than in patients with natriuresis below the median. This was the first evidence in favor of a modulating influence of dietary sodium on blood pressure-associated target organ lesions.

In addition to SAP, obesity as well as insulin resistance and smoking were shown to be associated with a level of AER inappropriately high for the SAP status




Figure 1—Prevalence of microalbuminuria (MA) (■) ( $\geq 20$  μg/min) or LVH (□) ( $\geq 125$  in men and 110 g/m<sup>2</sup> in women) in a cohort of 376 patients with never-treated essential hypertension aged  $\geq 40$  years.

(23). The influence of obesity and insulin resistance suggests that albuminuria may be linked to the presence of the metabolic syndrome. It was reported that in patients with the metabolic syndrome defined according to the Adult Treatment Panel III report, the prevalence of LVH and microalbuminuria was higher in patients with the metabolic syndrome than in patients without (30 vs. 24% for LVH and 11 vs. 8% for microalbuminuria) (24). A similar prevalence of target organ damage was found in a larger population; in fact, the prevalence of microalbuminuria increased with the number of components of the metabolic syndrome (from 3% in subjects without any abnormality to 9.8% in subjects with three abnormalities and 22.1% in subjects with five abnormalities) (25).

C-reactive protein is a sensitive marker of subclinical inflammation that was shown to be a good predictor of cardiovascular outcomes. In a cross-sectional study conducted in the large Groningen cohort, Stuveling et al. (26) observed that increasing C-reactive protein values from 0.2 to 10 mg/l resulted in a remarkable steepening of the slope of the relationship of albuminuria versus mean arterial pressure, with a potentiating effect of C-reactive protein that became significant for mean arterial pressures >90 mmHg.

With regard to plasma homocysteine as a predictor of clinical vascular disease, it was shown that this parameter was correlated with arterial stiffness assessed by the pulse wave velocity in hypertensive subjects with a mean age of 58 years (27). Nevertheless, the highest level of homocysteine was associated with the lowest level of glomerular filtration rate. Taking into account the fact that plasma homocysteine concentration is closely related to renal function (28), the significance of plasma homocysteine should be considered with great caution.

### ALBUMINURIA AND TREATMENT OF HYPERTENSION

— In the Treatment of Mild Hypertension Study (TOMS) conducted in patients with mild hypertension (diastolic blood pressure 85–99 mmHg), it was reported that the use of enalapril over 12 months afforded a larger decrease in albuminuria despite a similar achieved blood pressure decrease when compared with acebutolol, amlodipine, chlortalidone, and doxazosin (29). In the population of the LIFE study,

administration for 4.8 years of losartan (an angiotensin II receptor antagonist)- or atenolol (a  $\beta$ -blocker)-based treatment to a target blood pressure of 140/90 mmHg was associated with a more marked decrease in AER with losartan ( $-33$  vs.  $-25\%$  at the 1-year follow-up) (12). As in most studies on the long-term effect of treatment on target organ damage, the numbers as well as the characteristics of patients in whom no improvement in LVH or AER occurred were not disclosed. Efforts should be devoted to the issue of resistance of target organ damage despite adequate control of blood pressure. In a study conducted in 187 normoalbuminuric patients aged <50 years, with previously untreated hypertension and followed up for 2.7 years on various antihypertensive regimens including ACE inhibitors, Redon et al. (30) observed progression from normo- to microalbuminuria (AER  $\geq 30$  mg/24 h) in 11% of patients and less frequently in subjects treated with ACE inhibitors. Moreover, a tendency to a higher BMI, less reduction in blood pressure, and an increase in blood glucose and uric acid was found in “albuminuria progressors.” Analysis of the influence of obesity, insulin resistance, or the metabolic syndrome and more importantly sodium intake could be of great value in the search for causes of resistance of target organ damage despite satisfactory control of blood pressure.

### ALBUMINURIA AND RENAL OUTCOMES IN ESSENTIAL HYPERTENSION

— In population studies, no correlation between albuminuria and glomerular filtration rate (GFR) has been detected. In the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study conducted in nondiabetic residents of the city of Groningen (the Netherlands), it was observed that GFR estimated by 24-h creatinine clearance tended to be elevated in subjects with high-normal AER (15–30 mg/day), whereas macroalbuminuria was independently associated with a reduction in creatinine clearance below values expected for age and sex (4). In the Gubbio study conducted in a sample of an Italian community of 1,632 subjects aged 45–64 years, no relationship between increasing AER and the prevalence of “low” creatinine clearance (<60 ml/min) was found (31).

In the PREVEND cohort and within a follow-up period of 4 years, an incidence of de novo development of renal insuffi-

ciency (creatinine clearance <60 ml/min per 1.73 m<sup>2</sup>) of 4.2% was observed. Although age as well as serum cholesterol and glucose were higher, whereas baseline renal function was lower in this group of the population, multivariate analysis showed that baseline AER was a good predictor of the risk of developing impaired renal function (32). In a group of 486 aborigines (10.5% with type 2 diabetes at inclusion), Hoy et al. (33) reported on a close correlation between baseline albuminuria (range ACR <1.1 in 30% to >100 mg/mmol in 6.2% of the population) and the decline in GFR estimated by the Cockcroft and Gault equation within a follow-up period of 1–6 years. In fact, the annual decrease in GFR was almost negligible in normoalbuminuric people, but increased to 2.2 and 11.6 ml  $\cdot$  min<sup>-1</sup>  $\cdot$  year<sup>-1</sup> in micro- and macroalbuminuric subjects, respectively.

In patients with essential hypertension, no difference in GFR was detected between normo- and microalbuminuric individuals, and no alteration in intrarenal hemodynamics, including an increase in the filtration fraction that would be suggestive of elevated intra-glomerular pressure, was detected. Of interest, the renal vasodilatory response to acute administration of the ACE inhibitor captopril was significantly blunted in microalbuminuric subjects, despite a similar level of circulating renin. This suggested that microalbuminuria may be a marker of early intra-renal vascular dysfunction (34). In a minority of patients, hyperfiltration relative to a theoretical age-related value may be observed and associated with a slightly higher level of albuminuria (35). Whether microalbuminuria or hyperfiltration is a precursor of further renal alterations, as already reported in type 1 diabetes, remains to be documented.

In cross-sectional studies, age is strongly inversely correlated with GFR, and glomerular filtration progressively decreases during aging at a rate of  $\sim 0.5$  to 1 ml  $\cdot$  min<sup>-1</sup>  $\cdot$  year<sup>-1</sup>. Several factors were identified as accelerators of the age-related decline in GFR. In a recent study conducted in 195 normotensive subjects and 645 patients with never-treated hypertension, it was observed that the existence of hypertension and more precisely concentric LVH was associated with a marked acceleration of the age-related decline in GFR (36). Other cross-sectional studies have shown that the slope of the relationship age versus GFR is steeper in

Table 2—Morbidity mortality studies and albuminuria in nondiabetic patients

	Age range (years)	Population characteristics	Follow-up duration (years)	Outcome	Cutoff value of albuminuria
Copenhagen (43)	30–70	HT in 10–15%	5	CHD	>4.8 $\mu\text{g}/\text{min}$ (0.64 mg/mmol)
Monica (42)	30–70	Blood pressure <150/90 mmHg	10	CHD	>0.65 mg/mmol (5.1 $\mu\text{g}/\text{min}$ )
Hunt (44)	>20	Nondiabetic subjects	4.4	All-cause death	>0.76 mg/mmol (6 $\mu\text{g}/\text{min}$ )
Life (41)	55–80	Electrocardiogram LVH	4.8	Cardiovascular death, first myocardial infarction, stroke	>1.28 mg/mmol (10 $\mu\text{g}/\text{min}$ )
Hunt (45)	>20	Treated HT	4.3	All-cause death	>1.7 mg/mmol (13.3 $\mu\text{g}/\text{min}$ )
Hoorn (46)	50–75	Peripheral arterial disease	5	Cardiovascular death	>2 mg/mmol (16 $\mu\text{g}/\text{min}$ )
Utrecht (47)	52–67	Postmenopausal	20	Cardiovascular death	>2.4 mg/mmol (18 $\mu\text{g}/\text{min}$ )

CHD, coronary heart disease; HT, hypertension.

patients with impaired glucose tolerance or diabetes discovered during an oral glucose tolerance test (37).

Although a recent longitudinal study confirmed that the decline in GFR found in hypertensive subjects left untreated for 6 years is accentuated compared with a normotensive group ( $-1.22$  vs.  $0.12$  ml/min using  $99\text{m-Tc-DTPA}$  urinary clearance) (38), only a few studies have assessed the evolution of renal function during long-term antihypertensive treatment in individuals with normal renal function. In a retrospective study conducted in 141 patients (38% with microalbuminuria defined as 30–300 mg/day), it was shown that within the 7 years of follow-up, the decrease in 24-h creatinine clearance amounted to 12.1 in microalbuminuria vs. 7.7 ml/min in normoalbuminuric patients, and no influence of the type of antihypertensive regimen (containing or not containing an ACE inhibitor) was detected (39). Within a follow-up period of 14 years, a decrease in GFR, estimated by inulin clearance, of  $\sim 19$  ml/min was found in a small group of 23 hypertensive subjects adequately controlled by antihypertensive therapy (40). No relationship between baseline albuminuria and the yearly decline in GFR was reported in most studies (38,40). Of interest, the most important determinant of the GFR progression was the baseline level of blood pressure.

### ALBUMINURIA AND CARDIOVASCULAR OUTCOMES IN ESSENTIAL HYPERTENSION

In the last few years, several studies have pointed out the role of microalbuminuria as a predictor of cardiovascular morbidity (8,41,42) and mortality (8,43–46). The characteristics

of some of these important prospective studies are shown in Table 2. It clearly appears that threshold values of microalbuminuria that increase risk are consistently lower than the usually accepted cutoff points for microalbuminuria criteria. In studies performed in people aged >40 years, the risk of increased cardiovascular mortality was significant above ACR values of 1.28 (8) to 2 mg/mmol (45), which corresponds to AER of 10–16  $\mu\text{g}/\text{min}$  in timed urine collections. In contrast, in two studies conducted in populations aged 30–70 years (41,42) with ischemic heart disease as the primary end point, the threshold of ACR was 0.65 mg/mmol creatinine, roughly corresponding to AER of 5–6  $\mu\text{g}/\text{min}$ . The hypothesis that microalbuminuria may reflect generalized atherosclerosis was tested in the 5-year follow-up period of the Hoorn study (45) conducted in 50- to 75-year-old subjects. It was observed that both microalbuminuria (ACR >2 mg/mmol) and peripheral arterial disease (assessed by the ankle-brachial index) were associated with a fourfold increase in cardiovascular mortality, which was more marked in hypertensive subjects than in normotensive subjects; however, it was concluded that microalbuminuria affected mortality through a mechanism different from extensive atherosclerosis.

### ALBUMINURIA AND RENAL OUTCOMES IN TYPE 2 DIABETES

There have been several studies examining the relationship between microalbuminuria and renal outcomes in type 2 diabetes. Mogensen (1) studied the predictive value of microalbuminuria in patients with type 2 diabetes. It was predictive of the development of overt proteinuria as well as mortality. Pa-

tients with type 2 diabetes and albumin concentrations of 30–140  $\mu\text{g}/\text{ml}$  at baseline were more likely to develop clinically detectable proteinuria (>400  $\mu\text{g}/\text{ml}$ ) after 9 years of average follow-up than patients with baseline urinary albumin concentrations <30  $\mu\text{g}/\text{ml}$ . These findings were supported by Berrut et al. (2), who examined patients with type 2 diabetes and hypertension. The GFR of patients with microalbuminuria declined more than the GFR of patients with normoalbuminuria over the average 22 months of follow-up ( $P < 0.01$ ).

There have also been several larger trials that have shown the association between albuminuria and renal outcomes in patients with type 2 diabetes (Table 3). The Irbesartan Diabetic Nephropathy Trial (IDNT) examined 1,715 patients with hypertension, type 2 diabetes, and proteinuria. Patients enrolled in IDNT had urinary protein excretion of at least 900 mg/24 h and serum creatinine concentration between 1.0 and 3.0 mg/dl in women and 1.2 and 3.0 mg/dl in men at baseline (10). The risk for the development of end-stage renal disease or doubling of serum creatinine during the average 4 years of follow-up doubled for each doubling of baseline proteinuria level (hazard ratio [HR] 2.04, 95% CI 1.87–2.22) (47). Similarly, the Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study followed 1,513 patients with type 2 diabetes and nephropathy (9). Nephropathy was defined as a urinary ACR  $\geq 300$  mg/g with a serum creatinine level of 1.3–3.0 mg/dl. The presence of albuminuria was associated with an adjusted HR of 6.2 (95% CI 4.4–8.7;  $P < 0.001$ ) for the outcome of

Table 3—Albuminuria and renal outcomes in type 2 diabetes

	Number of patients	Study population	Mean follow-up	Intervention	Renal risk with albuminuria
IDNT (5,10,47)	1,715	Type 2 diabetes, hypertension	4 years	Irbesartan, amlodipine, or placebo	<ul style="list-style-type: none"> <li>• HR 2.04; 95% CI 1.87–2.22</li> <li>• Each 50% decrease in proteinuria in the first 12 months: reduction in renal risk (HR 0.44; 95% CI 0.40–0.49)</li> </ul>
RENAAL (3,7,9,48)	1,513	Type 2 diabetes	3.4 years	Losartan (50 mg or 100 mg) vs. placebo	<ul style="list-style-type: none"> <li>• HR 6.2; 95% CI 4.4–8.7</li> <li>• Each 50% decrease in albuminuria in the first 6 months: reduction in risk for end-stage renal disease of 45%</li> </ul>
MARVAL (49)	332	Type 2 diabetes	6 months	Valsartan vs. amlodipine	<ul style="list-style-type: none"> <li>• Urinary AER at 24 weeks was 56% (95% CI 49.6–63.0) of baseline with valsartan and 92% (95% CI 81.7–103.7) of baseline with amlodipine</li> </ul>
IRMA-2 (11)	590	Type 2 diabetes, hypertension	2 years	Irbesartan (150 mg or 300 mg) vs. placebo	<ul style="list-style-type: none"> <li>• HR for progression to overt nephropathy: in the 150 mg group: HR 0.56, 95% CI 0.31–0.99; in the 300 mg group: 0.32, 95% CI 0.15–0.65)</li> </ul>

doubling of serum creatinine or end-stage renal disease (3).

Multiple datasets have demonstrated that microalbuminuria is a potent risk factor for the development of progressive kidney disease. It portends the future development of overt proteinuria, doubling of serum creatinine, end-stage renal disease, and mortality. Because of this relationship, the association between reduction of albuminuria and renal outcomes was examined.

### TREATMENT OF ALBUMINURIA AND RENAL OUTCOMES IN TYPE 2 DIABETES

Several studies have shown that reduction of albuminuria by inhibition of the renin-angiotensin-aldosterone system is associated with the preservation of renal function. RENAAL was a randomized double-masked study of patients with type 2 diabetes and nephropathy comparing losartan (50–100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (9). In patients randomized to losartan, proteinuria declined by 35% compared with placebo. Losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction 25%;  $P = 0.006$ ) and end-stage renal disease (risk reduction 28%;  $P = 0.002$ ). Each 50% decrease in albuminuria in the first 6 months was associated

with a reduction in risk for end-stage renal disease of 45% (48). The decrease in albuminuria associated with losartan therapy was an important predictor of preservation of renal function.

Similarly, the IDNT trial compared the effects of irbesartan, amlodipine, and placebo in 1,715 hypertensive patients with type 2 diabetes and nephropathy (10). The risk of doubling the serum creatinine concentration was 33% lower in the irbesartan group than in the placebo group ( $P = 0.003$ ) and 37% lower in the irbesartan group than in the amlodipine group ( $P < 0.001$ ). Treatment with irbesartan was associated with a relative risk of end-stage renal disease that was 23% lower than that in both other groups. For each halving of proteinuria level between baseline and 12 months, with treatment, the risk for doubling of baseline serum creatinine level or the development of end-stage renal disease was reduced by more than half (HR 0.44, 95% CI 0.40–0.49) (47).

The Microalbuminuria Reduction with Valsartan (MARVAL) trial administered 80 mg/day valsartan or 5 mg/day amlodipine to 332 patients with type 2 diabetes and microalbuminuria (49). The urinary albumin excretion rate at 24 weeks was 56% (95% CI 49.6–63.0) of baseline with valsartan and 92% (95% CI 81.7–103.7) of baseline with amlodipine.

Blood pressure reductions were similar between the two treatments.

The use of angiotensin receptor blockers (ARBs) is clearly beneficial in reducing proteinuria, and this is associated with improving renal outcomes. In addition, increasing the dose of ARB has been found to have greater renoprotection, independent of blood pressure control. The Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA-2) study, which compared 150 and 300 mg irbesartan daily to placebo in 590 hypertensive patients with type 2 diabetes and microalbuminuria found the hazard ratio for progressing to overt nephropathy (urinary albumin excretion rate in an overnight specimen  $>200 \mu\text{g}/\text{min}$  and at least 30% higher than the baseline rate on at least two consecutive visits) was 0.56 in the 150 mg group (95% CI 0.31–0.99) and 0.32 in the 300 mg group (95% CI 0.15–0.65) (11). This was after adjustment for the baseline level of microalbuminuria and the blood pressure achieved during the study. Given the improvement in outcomes with higher doses of ARBs, there is now interest in whether doses beyond the current recommended dosage levels may provide increased RAAS blockade and therefore greater renoprotection. Irbesartan, 600 or 900 mg/day, compared to the current maximal daily dosage of 300 mg/day was given to 52 hypertensive type 2 diabetic patients with microalbu-

minuria also treated with other antihypertensive medications (50). Irbesartan, 900 mg/day, caused an additional 15% decrease in microalbuminuria compared with 300 mg/day irbesartan ( $P = 0.02$ ). In addition to increasing the dose of ACE inhibitors or ARBs, other potential ways to increase the inhibition of the rennin-angiotensin system include combining ACE inhibitors and ARBs, adding an aldosterone inhibitor, or adding a renin inhibitor.

## **ALBUMINURIA AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES**

**DIABETES** — A strong association has been reported between microalbuminuria and cardiovascular outcomes in patients with type 2 diabetes. An analysis of 3,498 patients with diabetes and 5,545 patients without diabetes in the Heart Outcomes Prevention Evaluation (HOPE) study found that microalbuminuria increased the adjusted relative risk (RR) of major cardiovascular events (RR 1.83, 95% CI 1.64–2.05) (6). Participants with diabetes had a RR of 1.97 (95% CI 1.68–2.31) and those without diabetes had an RR of 1.61 (95% CI 1.36–1.90).

The IDNT study, described above, also reported that albuminuria was an independent risk factor for cardiovascular events (5). The study defined a cardiovascular composite end point consisting of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, stroke, amputation, and coronary and peripheral revascularization. The ACR was associated with an increased risk of this cardiovascular composite end point (RR 1.29 per natural log unit, 95% CI 1.13–1.48). Data from the RENAAL study also demonstrated that the presence of albuminuria was associated with increased cardiovascular events (7). Cardiovascular events were defined as a composite of myocardial infarction, stroke, first hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, or cardiovascular death. It was found that patients with a high baseline ACR ( $\geq 3$  g/g) had a 1.92-fold higher risk (95% CI 1.54–2.38) for the cardiovascular end point and a 2.70-fold higher risk (95% CI 1.94–3.75) for heart failure compared with patients with low baseline levels of ACR ( $<1.5$  g/g).

Furthermore, Gimeno-Orna et al. (51) classified 436 type 2 diabetic patients into one of four groups based on if they

had baseline cardiovascular disease or microalbuminuria. Patients with no baseline cardiovascular disease, but microalbuminuria, had an increased RR for incident cardiovascular disease (RR 2.8, 95% CI 1.7–4.6) compared with patients with no baseline cardiovascular disease and normoalbuminuria. In addition, patients with no baseline cardiovascular disease and microalbuminuria had the same risk for a subsequent cardiovascular event as patients who had a previous cardiovascular event documented at baseline. Microalbuminuria was as potent a risk factor for cardiovascular events as a previous history of actual cardiovascular disease.

Microalbuminuria may also be a risk factor for more severe or advanced cardiovascular disease as well. The 330 patients who underwent coronary angiography were divided into groups based on the presence or absence of diabetes and the presence or absence of microalbuminuria (52). Diabetic patients with microalbuminuria had a higher prevalence of three-vessel coronary artery disease compared with those without microalbuminuria (75 vs. 42%). This relationship was also seen in those patients studied without diabetes and with or without microalbuminuria (39 vs. 20%).

Multiple lines of evidence demonstrate a strong association between the presence of microalbuminuria and the risk of adverse cardiovascular events. Evidence suggests that as the amount of urinary albumin excretion increases along the continuum from microalbuminuria to albuminuria and proteinuria, the risk of adverse cardiovascular events increases. Although this has been primarily studied in the diabetic population, evidence supports the presence of albuminuria as a potent risk factor for adverse cardiovascular events in the nondiabetic population as well. Data from the Framingham study showed that in 1,568 nonhypertensive participants without diabetes, urinary albumin excretion less than the microalbuminuria threshold predicted the development of cardiovascular disease (53). In the PREVEND study, urinary albumin was measured in 6,669 nondiabetic participants, and microalbuminuria was associated with cardiovascular disease (54). Indeed some studies have suggested that the presence of microalbuminuria increases the relative risk of an adverse cardiovascular event similarly to the presence of hypercholesterolemia (55). The presence of microalbuminuria may need to be viewed

in the same light as other risk factors such as blood pressure, cholesterol, and blood glucose.

## **TREATMENT OF ALBUMINURIA AND CARDIOVASCULAR OUTCOMES**

— In the PREVEND Intervention Trial (PREVEND IT), patients with albuminuria treated with foscipril experienced a significant decrease in urinary albumin excretion (26%) and a trend toward a decrease in cardiovascular events (40%) (56). In the LIFE study, patients with a urinary ACR greater than the median value at baseline (1.21 mg/mmol), but who were able to decrease their ACR to less than the median value at 1 year (0.67 mg/mmol), had a reduced risk for cardiovascular mortality, stroke, and myocardial infarction compared with patients who were not able to decrease their ACR (12). This suggests that there may be a cardiovascular benefit to reducing albuminuria in patients with essential hypertension but also in type 2 diabetes. Future trials are needed in patients with type 2 diabetes to explore the relationship between reduction in albuminuria and improvement in cardiovascular events.

**CONCLUSIONS** — The presence of albuminuria is a powerful predictor of renal and cardiovascular risk in patients with type 2 diabetes and hypertension. In addition, multiple studies have shown that decreasing the level of albuminuria reduces the risk of adverse renal and cardiovascular outcomes. The pathophysiology is not definitively known, but is hypothesized to be related to endothelial dysfunction, inflammation, or possibly abnormalities in the renin-angiotensin-aldosterone system.

Albuminuria is therefore an important risk factor to measure in patients at risk. The American Diabetes Association recommends that patients with type 2 diabetes be tested for albuminuria at the time of initial diabetes diagnosis and yearly thereafter (13). Initiation of ACE inhibitor or ARB therapy should be considered in patients with microalbuminuria or overt proteinuria. The level of albuminuria should be followed up during treatment, and doses of the ACE inhibitor or ARB should be titrated upward to maximize the beneficial effect on albuminuria. It is possible that the combination of ACE inhibitors and ARBs may provide additional benefit over ACE inhibitors or ARBs alone (57). In addition to

ACE inhibitors and ARBs, adequate blood pressure control is an important mainstay of treatment. If blood pressure is still elevated after maximal ACE inhibitor and/or ARB therapy, additional anti-hypertension medications should be added to maintain the blood pressure at <125/75 mmHg. Finally, additional agents such as statins, renin inhibitors, and glycosaminoglycans may provide additional albuminuria reduction and are actively being studied (58).

In summary, albuminuria is associated with adverse renal and cardiovascular outcomes, and decreasing albuminuria with ACE inhibitor or ARB therapy, blood pressure lowering, and/or other agents can lead to improved outcomes. Physicians should measure urinary albumin excretion in patients with type 2 diabetes and hypertension routinely and be as aggressive in treating this modifiable risk factor as they do blood pressure, cholesterol, or blood glucose.

References

1. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 310:356–360, 1984
2. Berrut G, Bouhanick B, Fabbri P, Guillo-teau G, Bled F, Le Jeune JJ, Fressinaud P, Marre M: Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. *Clin Nephrol* 48:92–97, 1997
3. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. *Kidney Int* 63:1499–1507, 2003
4. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE: Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. *J Am Soc Nephrol* 11:1882–1888, 2000
5. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA: Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. *Kidney Int Suppl* S50–S55, 2004
6. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 286:421–426, 2001
7. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 110:921–927, 2004
8. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhr-quist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. *J Hypertens* 22:1805–1811, 2004
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345:861–869, 2001
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345:851–860, 2001
11. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345:870–878, 2001
12. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhr-quist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. *Hypertension* 45:198–202, 2005
13. American Diabetes Association: Standards of medical care in diabetes. *Diabetes Care* 28 (Suppl. 1):S4–S36, 2005
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 39:S1–S266, 2002
15. Connell SJ, Hollis S, Tieszen KL, McMurray JR, Dornan TL: Gender and the clinical usefulness of the albumin: creatinine ratio. *Diabet Med* 11:32–36, 1994
16. Pontremoli R, Sofia A, Ravera M, Nicoletta C, Viazzi F, Tirota A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G, Deferrari G: Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study: Microalbuminuria: A Genoa Investigation on Complications. *Hypertension* 30:1135–1143, 1997
17. Palatini P, Mormino P, Mos L, Mazzer A, Dorigatti F, Zanata G, Longo D, Garbellotto R, De Toni R, Graniero G, Pessina AC: Microalbuminuria, renal function and development of sustained hypertension: a longitudinal study in the early stage of hypertension. *J Hypertens* 23:175–182, 2005
18. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. *J Hypertens* 20:405–412, 2002
19. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B: Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA* 292:2350–2356, 2004
20. Fesler P, du Cailar G, Ribstein J, Mimran A: Heterogeneity of cardiorenal characteristics in normotensive subjects. *Hypertension* 43:219–223, 2004
21. Ribstein J, Halimi JM, du Cailar G, Mimran A: Renal characteristics and effect of angiotensin suppression in oral contraceptive users. *Hypertension* 33:90–95, 1999
22. du Cailar G, Ribstein J, Mimran A: Dietary sodium and target organ damage in essential hypertension. *Am J Hypertens* 15:222–229, 2002
23. Mimran A, Ribstein J, DuCailar G, Halimi JM: Albuminuria in normals and essential hypertension. *J Diabetes Complications* 8:150–156, 1994
24. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Leonetti G, Magrini F, Zanchetti A: Metabolic syndrome and target organ damage in untreated essential hypertensives. *J Hypertens* 22:1991–1998, 2004
25. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U.S. adults. *Ann Intern Med* 140:167–174, 2004
26. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, de Jong PE, Gans RO, de Zeeuw D: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. *Hypertension* 43:791–796, 2004
27. Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J: Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. *Hypertension* 34:837–842, 1999
28. Bostom AG, Culleton BF: Hyperhomocysteinemia in chronic renal disease. *J Am Soc Nephrol* 10:891–900, 1999
29. Abraham PA, Mascioli SR, Launer CA, Flack JM, Liebson PR, Svendsen KH,

- Grandits GA, Opsahl JA, Schoenberger JA, Grimm RH Jr: Urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in mild hypertension. *Am J Hypertens* 7:965–974, 1994
30. Redon J, Rovira E, Miralles A, Julve R, Pascual JM: Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. *Hypertension* 39:794–798, 2002
31. Cirillo M, Laurenzi M, Panarelli P, Mancini M, Zanchetti A, De Santo NG: Relation of urinary albumin excretion to coronary heart disease and low renal function: role of blood pressure. *Kidney Int* 65:2290–2297, 2004
32. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE: An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. *Kidney Int Suppl* S18–S21, 2004
33. Hoy WE, Wang Z, VanBuynder P, Baker PR, Mathews JD: The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. *Kidney Int* 60:243–248, 2001
34. Mimran A, Ribstein J, DuCailar G: Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? *Hypertension* 23:1018–1021, 1994
35. Mimran A, Ribstein J, Du Cailar G: Microalbuminuria in essential hypertension. *Curr Opin Nephrol Hypertens* 8:359–363, 1999
36. Fesler P, Du Cailar G, Ribstein J, Mimran A: Left ventricular remodeling and renal function in never-treated essential hypertension. *J Am Soc Nephrol* 14:881–887, 2003
37. Ribstein J, Du Cailar G, Mimran A: Glucose tolerance and age-associated decline in renal function of hypertensive patients. *J Hypertens* 19:2257–2264, 2001
38. Fesler P, Ribstein J, du Cailar G, Mimran A: Determinants of cardiorenal damage progression in normotensive and never-treated hypertensive subjects. *Kidney Int* 67:1974–1979, 2005
39. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. *J Hypertens* 16:1325–1333, 1998
40. Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J: Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. *Am J Hypertens* 9:841–849, 1996
41. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. *Arterioscler Thromb Vasc Biol* 19:1992–1997, 1999
42. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS: Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation* 110:32–35, 2004
43. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study: The Nord-Trondelag Health Study (HUNT), Norway. *Am J Kidney Dis* 42:466–473, 2003
44. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H: Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. *Circulation* 108:2783–2789, 2003
45. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. *Arterioscler Thromb Vasc Biol* 19:617–624, 1999
46. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PE, de Zeeuw D, van Der Schouw YT: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. *Circulation* 103:3057–3061, 2001
47. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. *Am J Kidney Dis* 45:281–287, 2005
48. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int* 65:2309–2320, 2004
49. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 106:672–678, 2002
50. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. *Kidney Int* 68:1190–1198, 2005
51. Gimeno-Orna JA, Molinero-Herguedas E, Sanchez-Vano R, Lou-Arnal LM, Boned-Juliani B, Castro-Alonso FJ: Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. *Diabetes Res Clin Pract* 74:103–109, 2006
52. Sukhija R, Aronow WS, Kakar P, Garza L, Sachdeva R, Sinha A, Mehta JL: Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. *Am J Cardiol* 98:279–281, 2006
53. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 112:969–975, 2005
54. Stuveling EM, Hillege HL, Bakker SJ, Asselbergs FW, de Jong PE, Gans RO, de Zeeuw D: C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. *Atherosclerosis* 172:107–114, 2004
55. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. *Hypertension* 35:898–903, 2000
56. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH: Effects of fasinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. *Circulation* 110:2809–2816, 2004
57. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. *J Am Soc Nephrol* 14:992–999, 2003
58. Epstein M: Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy. *Nat Clin Pract Nephrol* 2:310–311, 2006